

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5042125

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	F1 ONCOLOGY, SEZC	07/06/2017
RECEIVING PARTY DATA		
Name:	F1 ONCOLOGY, INC	
Street Address:	625 N. FLAGLER DR., SUITE 625	
City:	WEST PALM BEACH	
State/Country:	FLORIDA	
Postal Code:	33401	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15644778
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	561-650-5048	
Email:	gschreiber@f1oncology.com	
Correspondent Name:	GREG SCHREIBER	
Address Line 1:	625 N. FLAGLER DR., SUITE 625	
Address Line 4:	WEST PALM BEACH, FLORIDA 33401	
ATTORNEY DOCKET NUMBER:	F1.001.US.02	
NAME OF SUBMITTER:	MICHAEL MAND	
SIGNATURE:	/Michael Mand/	
DATE SIGNED:	07/10/2018	
Total Attachments: 3		
source=F1.001.P03 WO.01 US.01 TW.01 US.02 WO.02 TW.02 2017 07 06 F1 SEZC to F1 US#page1.tif		
source=F1.001.P03 WO.01 US.01 TW.01 US.02 WO.02 TW.02 2017 07 06 F1 SEZC to F1 US#page2.tif		
source=F1.001.P03 WO.01 US.01 TW.01 US.02 WO.02 TW.02 2017 07 06 F1 SEZC to F1 US#page3.tif		

ASSIGNMENT

In consideration of good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, effective as of the signature date of the Assignor below, the undersigned **F1 Oncology, SEZC**, a corporation of The Cayman Islands, whose address is having a place of business at BritCay House, 236 Eastern Avenue, Grand Cayman, Cayman Islands ("Assignor") does hereby assign, sell and transfer to:

F1 Oncology, Inc., a corporation of the State of Delaware having a place of business at 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401, USA ("Assignee"),

its successors and assigns, the entire right, title and interest in the invention and/or improvements of the undersigned disclosed in the patent applications and other rights shown below:

- (a) U.S. Ser. No. 62/467,039 filed March 3, 2017 entitled Ex Vivo Propagation-Free Gene Transduction Vectors and Regulatory Domains for Adoptive Cellular Therapy (Docket No. F1.001.P03), and naming Inventors Gregory Ian Frost, James Joseph Onuffer, and Ghiabe H. Guibinga, and Applicant F1 Oncology; and,
- (b) International Appln. No. PCT/US2017/023112 filed March 19, 2017 entitled Methods and Compositions for Transducing Lymphocytes and Regulated Expansion Thereof (Docket No. F1.001.WO.01), and naming Inventors/Applicants Gregory Ian Frost, Ghiabe H. Guibinga, and Anirban Kundu, and Applicant F1 Oncology, Inc.; and,
- (c) U.S. Ser. No. 15/462,855 filed March 19, 2017 entitled Methods and Compositions for Transducing Lymphocytes and Regulated Expansion Thereof (Docket No. F1.001.US.01), and naming Inventors/Applicants Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, and Anirban Kundu, and Applicants F1 Oncology, SEZC and F1 Oncology, Inc.; and,
- (d) Taiwan patent application no. 106109186 filed March 20, 2017 entitled Methods and Compositions for Transducing Lymphocytes and Regulated Expansion Thereof (Docket No. F1.001.TW.01), and naming Inventors/Applicants Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, and Anirban Kundu, and Applicants F1 Oncology, SEZC and F1 Oncology, Inc.; and,
- (e) U.S. Ser. No. 15/644,778 filed July 8, 2017 entitled METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF (Docket No. F1.001.US.02), and naming Inventors Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, and Farzad Haerizadeh, and Applicant F1 Oncology, Inc.; and,



- (f) International Appln. No. PCT/US2017/41277 filed July 8, 2017 entitled METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF (Docket No. F1.001.WO.02), and naming Inventors Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, and Farzad Haerizadeh, and Applicant F1 Oncology, Inc.; and,
- (g) Taiwan Appln. No. 106123053 filed July 10, 2017 entitled METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF (Docket No. F1.001.TW.02), and naming Inventors Gregory Ian Frost, James Joseph Onuffer, Ghiabe H. Guibinga, and Farzad Haerizadeh, and Applicant F1 Oncology, Inc.; and,
- (h) any and all inventions, improvements, know-how, and other subject matter described, disclosed, or contained (whether claimed or not) in any of the foregoing applications and patents, whether developed solely or jointly with others; and,
- (i) the right to file foreign applications under the provisions of any convention or treaty and claim priority based on any of the foregoing applications in the United States or any other country; and,
- (j) all international, divisional, continuing, design, utility model, substitute, renewal, reissue, reexamination, and all other applications for patent which have been or shall be filed in the United States and all foreign countries that claim priority to or through, any of the foregoing applications; and,
- (k) all original, reissued and reexamined patents which have been or shall be issued in the United States or any other country on or resulting from any of the applications referenced in one or more of (a) through (g) above; and,
- (l) the copyright in any and all material described, disclosed, or contained in the foregoing applications and patents; and,
- (m) any and all other rights described in or provided by any of the above.

The undersigned Assignor warrant itself to be the owner of the entire right, title and interest in said invention or improvements and other rights in the same and to have the right to make this assignment, and further warrant that there are no outstanding prior assignments,

licenses, or other encumbrances on the interest herein assigned.

The undersigned hereby authorize and request all patent offices to issue any Patents and/or other rights resulting from any of the applications and/or rights referenced in one or more of (a) through (m) above to said Assignee. The undersigned hereby authorize and request the attorneys of record in said applications to insert in this assignment the filing dates and serial numbers of said applications when officially known, and the date of filing of the applications.

For said considerations the undersigned hereby agree, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all applications for said invention or improvements, and any necessary oaths, affidavit or declaration relating thereto, and any application for the reissue or extension of any Patent that may be granted upon said application and any and all applications and other documents for Patent and/or other rights on said invention or improvements, or other rights, that said Assignee, its successors or assigns may deem necessary or expedient, and for the said considerations the undersigned authorize said Assignee to apply for patents and/or other rights for said invention or improvements in its own name in such countries where such procedure is proper and further agree, upon the request of said Assignee, its successors and assigns, to cooperate to the best of the ability of the undersigned with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents and/or other rights, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain, maintain and enforce said Patents and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Patents and/or other rights will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Patents and/or other rights will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.

<p><u>Signature by Assignor:</u></p>  <p>Name: Laurel Martin Position: Vice President Finance, Controller For: F1 Oncology, SEZC Date: JULY 6, 2017</p>	<p><u>Accepted by Assignee/Recipient:</u></p>  <p>Name: Gregory I. Frost Position: Chairman and CEO For: F1 Oncology, Inc. Date: July 6th 2017</p>
--	---